Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) receptor , is showing promising results in early clinical assessments . Current examination https://bookmarkmiracle.com/story205441/retatrutide-emerging-investigations-and-projected-therapeutic-applications